Table 1 Timeline table of the case report
Dates | Relevant Past Medical History and Interventions | ||
|---|---|---|---|
January 2021 | A 9-year-old non obese male patient, diagnosed with T-ALL, with no medical history. | ||
Dates | Summaries from Initial and Follow-up Visits | Diagnostic Testing (including dates) | Interventions |
August | Intense holocranial headache, visual blurring and diplopia. Physical examination was normal. | 1/RT-qPCR for SARS-CoV-2: positive 2/LP: normal CSP components, negative culture with normal cytological result. | Clinical monitoring |
2021 | Persistent symptoms | 1/Ophthalmological examination: bilateral stage II papilledema and paralysis of the sixth right cranial nerve. 2/MRI and MRV: normal 3/LP: elevated opening pressure | Acetazolamide 125 mg per day |
August 2021 | Persistent diplopia, visual blurring and headache. | 1/RT-qPCR for SARS-CoV-2: positive 2/LP: normotensive CSF | 1/Acetazolamide 500 mg per day. 2/LP: A volume of 20 ml of CSF was taken. |
September 2021 | Improvement of the headache after LP but persistence of visual disturbances. Diplopia disappeared within a week after dose adjustment of treatment. | 1/ RT-qPCR for SARS-CoV-2: negative 2/ Ophthalmological examination: persistent papilledema | Acetazolamide 500 mg per day |